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 Abstract 
Background: The publication of large multicentre studies devoted to Continuous Renal 
Replacement Therapies (CRRT) in critically ill patients may influence the bedside prescription 
and practical application of the treatment. Despite this, many aspects of this therapy may not 
be informed by evidence, but remain a product of clinician preference.  Little is known about 
the current CRRT practice in Australian and New Zealand (ANZ) ICUs and it is not known if the 
evidence from recent studies has been integrated into practice. 
Design and Setting: A prospective on-line survey of CRRT practice was sent to ICU clinicians 
(medical and nursing) via three different national databases in ANZ ICUs during December 
2013 to March 2014. 
Results: There were 194 respondents from 106 ICUs: 49 ICUs (47%) were in tertiary 
metropolitan hospitals.  One hundred and two respondents (52%) reported CVVHDF as the 
most common CRRT technique with the combination of pre and post-dilution of replacement 
solutions.  There is variability in the prescription of dosing for CRRT with respondents 
indicating the therapy based on litres per hour (53%) or a weight adjusted treatment in 
mls/kg/hr (47%).   
For all modes of CRRT, the common blood flow rates applied were 100-150 and 150-200 
ml/min; with few respondents reporting flow rates < 150 or > 300 ml/min. Unfractionated 
heparin was the most common (83%) anticoagulant followed by regional citrate. Femoral 
vascular access was preferred and typically a 20cm length device inserted with Bard Niagara® 
and Arrow® access catheters most frequently used. The Baxter/Gambro  
 Prismaflex was the dominant machine platform with 71% of respondents indicating its use 
in their ICUs. 
Conclusions: These results provide insight into existing clinical management of CRRT. 
Considerable variation still exists in the practical prescription of CRRT in ANZ ICUs. 
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 Introduction 
Acute kidney injury is a significant and recognized complication of critical illness that affects 
2-7% 1-3 of hospitalized patients and up to 34% of critically ill patients. 4-6 AKI can result in 
severe derangements in fluid, electrolyte and acid-base balance requiring the intervention of 
supportive strategies. The use of Renal Replacement Therapy (RRT) forms a key component 
in the treatment for severe AKI and its use is required in up to 5-6% of all critically ill patients 
in intensive care units (ICUs).7  
The technical application of RRT has been highlighted in recent years with several large 
multicentre randomized controlled trials8-9 investigating ‘technique’ and ‘dose’ and 
association with mortality as the primary outcome. In the ‘RENAL’ study8 1464 patients 
receiving Continuous Renal Replacement Therapy (CRRT), specifically continuous veno-
venous haemodiafiltration (CVVHDF), were explored at different dose intensities and results 
indicated no difference in 90 day mortality. Similarly, in the ‘ATN’ study9 1124 patients 
receiving Intermittent Haemodialysis (IHD), Slow Low Efficiency Daily Dialysis (SLEDD) and 
CVVHDF at different dose intensities also indicated no difference in 60 day mortality. 
Technical information pertaining to the application of RRT for the treatment of AKI was 
illustrated in several pre study practice surveys.10-11 Technical aspects such as modality, dose, 
dose prescription, replacement/dialysate fluid type, blood flow rate, pre/post dilution for 
replacement fluid and machine types were explored in detail. More recently, two 
international groups have investigated the current management, practices and practitioner 
beliefs following the dissemination of results from both the RENAL and ATN trials.12-13 Of 
particular importance is whether CRRT practices have changed in response to these studies. 
These later surveys have however concentrated on dose, modality and timing of RRT with 
limited information regarding practical or technical aspects associated with the application of 
therapy.  
To date there has been no data published describing alteration in practice for Australian and 
New Zealand intensive care clinicians following outcomes of the RENAL or ATN studies.  In 
addition to practice changes following the results of these studies, there have been significant 
enhancements to capacity and flexibility in functionality of CRRT machines since the pre 
RENAL practice survey conducted in 2004. This improvement in machine design and 
functionality may have prompted changes to prescribing practices of CRRT in many ANZ ICUs.  
The aim of this survey was to establish the current practical prescription of CRRT in ICUs caring 
for adult and paediatric patients in ANZ.  
Methods 
Survey method 
A descriptive online survey was distributed from December 2013 to March 2014 requesting 
information from clinicians about their current practical application of CRRT.  A sample of ICU 
medical and nursing staff was accessed via three separate databases. The Australian and New 
Zealand Intensive Care Society Clinical Trials Group (ANZICS CTG), the Intensive Care 
Coordination and Monitoring Unit (ICCMU) ICU Connect list server and the Australian College 
of Critical Care Nurses (ACCCN) databases were used to seek participants for the survey. Ethics 
approval was granted by the Austin Health Human Research Ethics Committee (project No. 
04918) prior to study commencement. Consent to participate was implied by submission or 
return of the questionnaire.  
 
Survey Design 
The survey was devised from the pre ‘RENAL study’ practice questionnaire conducted in 34 
ANZ ICU’s in 2004 and published in 2008.10 The tool used for this survey was a modification of 
the eleven-point questionnaire and consisted of 20 questions. (A copy of the survey is 
available online as supplementary material). Demographic questions included the 
practitioners’ state or territory, study site (hospital), professional role (Intensivist, Nurse Unit 
Manager etc) and type of intensive care (adult, paediatric). In addition respondents were 
asked to identify the number of beds and type of ICU (metropolitan tertiary, private etc) as 
well as the number of patients they treated with CRRT each year. Twelve questions focused 
on the prescription of CRRT, including specification of the modalities of CRRT used 
(haemofiltration, haemodialysis, haemodiafiltration); specification of prescribed blood flow 
rate; if they prescribed CRRT on the basis of patient weight or alternatively litres per hour and 
prescribed replacement or combined with dialysate flow rates. The respondents were also 
asked to identify the preferred anatomical site for vascular access, the catheter type and usual 
length of catheter, the anticoagulation regimen used and type of machine used for CRRT.  
Statistical analysis 
Descriptive statistics were used for all demographic and clinical data and for all items in the 
survey. Data were cleaned and checked for missing values and invalid responses. The prime 
reporting statistics were expressed as frequencies and percentages. Statistical analyses were 
performed using Stata version 11 (Statacorp).  
 
Results 
Characteristics of the cohort 
Survey invitations were emailed to 4115 potential participants via ACCCN (1853), ICCMU 
(1652) and ANZIC’s clinical trials group (600) membership. There is likely duplication between 
these databases, with an unknown number of people appearing on two, or all three databases 
so it was not possible to know the precise number of invitees. One hundred and ninety four 
responses were received with 106 intensive or critical care units from ANZ represented. 
Overall, the majority of respondents came from New South Wales (26%) and Victoria (27%). 
Most respondents worked in metropolitan ICUs (73%), with the largest group working in 
metropolitan level three tertiary institutions (47%) caring for adult patients only (69%) (Table 
1). Consultant intensivists represented 19% of the total responses with clinical educators 
(19%), clinical nurses specialists (24%) and registered nurses (22%) filling the larger part of 
nursing roles. One third (36%) of respondents worked in units of 6-10 beds with 24% working 
in ICU’s > 20 beds. One quarter (25%) of respondents indicated their ICU treated > 100 
patients per year with some form of CRRT. 
CRRT Mode and Dose 
There was obvious clinical variation in the dose prescription for CRRT. Fifty three percent of 
respondents indicated the standard treatment dose of CRRT was prescribed in their ICUs in 
litres per hour, whilst 47% indicated a prescription aimed at a weight based dosing strategy 
of mls/kg/hr. The most common CRRT technique was Continuous Veno-Venous 
Haemodiafiltration (CVVHDF), with 54% of respondents indicating they ‘always’ use this  
 
mode of therapy. In contrast 9% and 2% indicated they ‘always’ have Continuous Veno-
Venous Haemofiltration (CVVH) or Continuous Veno-Venous Haemodialysis (CVVHD) 
prescribed in their ICUs respectively.  
CVVHDF in combination with pre and post fluid replacement (pre and post dilution) was 
indicated by respondents as ‘always’ prescribed in 29% of treatments with predilution 
CVVHDF (13%) and postdilution CVVHDF (12%) the next most used practices. If CVVHDF was 
prescribed in a standardized dose of litres per hour (L/hr), respondents reported a dose 
between 1) L/hr for dialysis (D) + 1  L/hr  as replacement (R) fluid  frequently or always used 
in 39% of treatments with a dose 2(D) L/hr + 2(R) L/hr in 38% of cases. CVVHDF set at 16-25 
mls/kg/hr was the most common weight based regimen with 47% frequently or always 
prescribing this dose, while > 25mls/kg/hr (39%) was the next most utilized dosing regimen 
(Table 2). 
If CVVH was prescribed in a standardized dose of litres per hour (L/hr), respondents reported 
a dose between 2-3 L/hr as frequently or always used in 20% of treatments with a dose > 3 
L/hr in only 9% of cases. CVVH set at > 25 mls/kg/hr was the most common weight based 
regimen with 16% frequently or always prescribing this dose (Table2).  
Blood flow rate  
A blood pump speed (set blood flow rate) of 150-200 mls/min was  ‘frequently’ or ‘always’ 
used in 59% of CVVHDF and 60% of CVVH treatments respectively. A prescribed rate of 200-
250 mls/min was the next most used with 46% (CVVHDF) and 50% (CVVH) respondents 
‘frequently’ or ‘always’ using this range (Table 2). Fifty one percent of respondents  
 
suggested the blood flow rate for CRRT was prescribed by unit policy or protocol, with 29% 
prescribed by medical staff and 20% set by the allocated bedside nurse. 
The management of frequent CRRT machine alarms included the manipulation of blood flow 
rate in an attempt to decrease alarm conditions such as elevated Transmembrane Pressure 
(TMP), high return or venous pressures with 34% of respondents indicating they ‘frequently’ 
alter the pump speed to alleviate alarm conditions in an attempt to continue therapy.  
Vascular Access 
The right and left femoral vein were favoured as the access site of choice for CRRT (Table 3). 
The next most common site was the right internal jugular vein with few respondents 
indicating the use of subclavian veins. Bard Niagara® and Arrow® catheters were the most 
frequently used access devices with a length of 20 cm preferred for all access sites. 
Anticoagulation 
Unfractionated heparin was the anticoagulation of choice with 83% of respondents either 
‘frequently’ or ‘always’ using this medication regimen to extend circuit life in CRRT. Regional 
techniques were less likely to be utilised with regional heparin and protamine (18%) and 
regional citrate in combination with CVVHDF (21%) ‘frequently’ or ‘always’ used. Eighty 
percent of respondents indicated they ‘occasionally’ used a ‘no anticoagulation’ strategy in 
place of drug based anticoagulation treatment for CRRT (Figure 1). 
 
 
 
Machines 
The most commonly used CRRT machine was the Prismaflex (Baxter Gambro, Deerfield, USA) 
(71%), followed by Aquarius (Nikisso, San Diego, USA) (27%), Prisma (Baxter Gambro, 
Deerfield, USA) (8%) and Infomed HF440 (Infomed, Geneva, Switzerland) (5%).  
Discussion 
Summary of major findings 
Clinical practice prescriptions for the management of CRRT in ANZ ICUs were assessed in this 
study with five key findings identified. First, CVVHDF was the mode of CRRT most commonly 
used, typically using a combination of pre and post filter fluid replacement. Second, 
approximately half the respondents indicated their practice was to adjust the dose of therapy 
according to body weight (mls/kg/hr), while half of the respondents used a standardised dose 
(litres per hour). Third, prescribed blood flow rate was highly variable, although 150-200 
mL/min was the most commonly prescribed rate for CVVH and CVVHDF. Fourth, the femoral 
veins were the sites of choice for vascular access. Finally, unfractionated heparin is the most 
commonly used anticoagulant used in CRRT.     
Contrast with previous studies 
The Australian and New Zealand Intensive Care Society (ANZICS) Centre for Outcome and 
Resource Evaluation assumes that by ANZICS definitions14 for patient acuity managed, all level 
2 and level 3 intensive care units (public and private hospitals) are capable of performing renal 
replacement therapy in ANZ. If we continue this assumption the cohort of RRT capable ICUs 
would number 145. Three quarters (n=106, 73%) of these ICUs completed  
 
the survey, suggesting a strong representation of units capable of performing RRT in ANZ. In 
2001, Silvester and colleagues reporting on the management and epidemiology of acute renal 
failure, investigated aspects of RRT practice in 81 Australian ICUs.15 Technical aspects in this 
study were limited to vascular access site, anticoagulation and mode of therapy. The only 
other reported study into local CRRT practices was prior to the RENAL study which 
investigated 34 participating trial ICUs in ANZ.10 This study conducted in 2004 investigated the 
technical and practical application of the therapy and served as the foundation for the current 
survey.  
Internationally, the BEST kidney study1 investigated world-wide CRRT practice in 54 centres 
across 23 countries following the introduction of consensus guidelines and recommendations 
from the Acute Dialysis Quality Initiative (ADQI) in 2002. This multi-national, multicentre study 
investigated technical aspects of the therapy including modality, dose, dilution method, 
membrane type and blood flow. The VA/NIH Acute Renal Failure Trial Network (ATN) pre 
study practice survey11 reported the findings from 130 practitioners in 27 medical centres in 
the US. Nine of the 26 questions specifically related to CRRT prescription, including estimation 
of frequency of use, vascular access (arterial, venous), mode, blood flow rates, type of fluids 
and dose prescription. Perhaps the largest survey investigating RRT practice involved 560 
European critical care nephrology conference participants.16 The majority of the respondents 
were nephrologists (52%) with CRRT prescribing physicians accounting for 25% of the 
responses. The technical aspects surveyed related to dose, modality and anticoagulation with 
more detailed technical prescription not addressed.  
 
 
Since the RENAL (2009)8 and ATN (2009)9 studies, there has been limited investigation to 
alteration in practice and prescription of CRRT, despite the publication of the respective 
findings from these two large, and potentially influential studies. In 2010, the European 
Society of Intensive Care Medicine (ESICM) investigated the current practices associated with 
RRT from 272 physicians.12 Despite a high number of respondents; the survey had limited 
technical description of technique and prescription, but did provide insight into practices 
relating to dose, modality and intensivists’ beliefs regarding the optimal management of RRT. 
A survey of 167 ICUs (intensivists) in 2009/10 investigated the management of AKI and RRT in 
UK.13 Modality and dose were addressed with little information of specific technical 
prescription. Our survey with a large representative sample from ANZ ICUs is the largest 
examination of the technical prescription of CRRT since publication of, and the 
recommendations from the RENAL and ATN studies. 
Mode of therapy 
The dominant mode of CRRT in ANZ is CVVHDF with 54% of respondents indicating they 
always use this mode with CVVH (9%) and CVVHD (2%) less frequently favoured. Prior to the 
RENAL study, 62% of ICUs (21/34) indicated CVVHDF as their preferred mode.10 ICUs had 
previously reported a higher use of CVVH with 35% (12/34 ICU’s) compared to our findings.10 
Internationally there remains great variation in practice in relation to modality of choice. The 
ESICM survey reported only a slight favour towards CVVHDF (51%) compared to CVVH (41%).12 
In the United Kingdom (UK), CVVH is the dominant mode (56%) compared to CVVHDF (37%).13 
In the United States (US), the pre ATN practice survey conducted in 2003 indicated that 112 
(86%) of practitioners prescribed some form of CRRT in the 27 sites  
 
investigated.11  Of these responders, the majority used CVVHD (78/112), followed by CVVHDF 
(67/112) with CVVH used in less than a third of patients requiring continuous artificial renal 
support. It appears from these data that where nephrologists are prescribing and or closely 
advising intensivists in the US, dialysate or diffusion is a mainstay for the prescription by 
mode. e.g. CVVHD or CVVHDF.  
The use of CVVHDF and CVVH requires the administration of replacement solution. Our data 
suggests for both these modes that a combination of pre and post dilution replacement is 
favoured by a third of respondents. Historically, there is variability with some ICUs exclusively 
using pre or post only sites for substitution. In contrast to our findings, the pre RENAL survey 
reported 94% of ICUs using a predilution approach in CVVH and CVVHDF, 10 suggesting a 
change in practice over the past 10 years. The BEST kidney study reported a slight favour for 
pre dilution (58%) compared to post dilution only (41%).1 The recent UK13 and ESICM12 surveys 
demonstrated similar findings to our own where a combination of pre and post was most 
commonly used with typically 30-50% of replacement fluid delivered predilution. It is likely 
given the technological advancement of the machines used for CRRT that this change in 
practice may be a common occurrence. Recent machines as cited in this report now have the 
capacity to deliver replacement fluid both pre and post filter with new software and added 
roller pumps to achieve this dual pathway simultaneously. Therefore the prescription may 
simply be because this is possible, or where clotting occurs commonly in the both the filter or 
membrane and the post filter bubble trap within the circuit, dilution into the blood path 
targets these two points to prevent clotting : pre and post dilution17. 
 
 
Dose 
In the pre RENAL practice survey no ANZ ICU reported dosing CRRT according to patient 
weight. During similar time period there was minimal prescribing of CRRT according to weight 
in other practice surveys. In the US < 20% of practitioners based the dose on patient weight 
with the majority (80%) prescribing at least 35 mls/kg/hr.11 Ricci and colleagues described 
uncertainty particularly by intensivists to treatment prescription, however indicated a dose of 
35 mls/kg/hr or 2-3 L/hr as the target.16 The BEST study reported treatment doses in mls/hr 
with a median standardised CRRT dose of 2 L/hr with a calculated weight adjusted dose of 
20.4 ml/kg/hr.1   
 A decade on, we report that half the ICUs in ANZ describe a weight based dosing prescription 
of mls/kg/hr. Further, a CVVHDF dose of 16-25 mls/kg/hr was the most common dose 
followed by > 25 mls/kg/hr. If CVVH was the mode of choice, a dose of > 25 mls/kg/hr was the 
most frequently used. For those ANZ ICUs prescribing litres per hour, a dose of 1 L/hr R and 1 
L/hr D is the most common in CVVHDF and 2-3 L/hr in CVVH mode. In contrast the ESICM 
survey described a median CRRT dose of 35 mls/kg/hr with < 15% prescribing a standard fixed 
ultrafiltrate dose irrespective of body weight.12 Similar to the European survey, 73% of UK 
ICUs use a protocol for CRRT dose with a CVVH dose of 35 mls/kg/hr being the most frequent 
prescription.13  
Blood Flow Rate  
One aspect of practice with ongoing variation is the speed of blood flow in the extracorporeal 
circuit. Prior to more advanced CRRT technology, blood flow rates of 150-200  
 
ml/min were common. Certainly the ANZ data from 200410 indicated a median blood flow rate 
of 200 ml/min with the BEST kidney study1 and pre practice ATN study11 reporting a median 
rate of 150 ml/min. Interestingly, in the country breakdown Japan median blood flow rate was 
80 ml/min whereas Australia, Netherlands, Portugal and the UK median blood flow rate of 
200 ml/min. Our study revealed that while 150-200 ml/min was still the dominant setting for 
all CRRT modes, a faster rate of 200-250 ml/min is now commonplace in the ANZ setting. 
While we do not have any data on blood flow rates from recent practice surveys, 
observational studies report practices between 10018  and > 30019 ml/min indicating great 
variability and limited evidence for best practice for this particular setting of the therapy.  
Vascular access 
Vascular access site for CRRT may be the most important variable for circuit life success. 20-22 
As such, there is much literature devoted to access site, type, design and catheter related 
complications.23-30 The internal jugular site is traditionally considered to be preferable to 
femoral venous access20,31 and supported by ADQI and Kidney Disease Improving Global 
Outcomes (KDIGO) consensus guidelines.32,33 Despite this, femoral access catheters are 
frequently used in the delivery of CRRT19,26 and may have a lower incidence of dysfunction26 
and colonization compared to jugular position in patients with lower body mass index (BMI).27 
Access site in relation to right and left venous positions have also been investigated with some 
studies suggesting longer circuit lifespans with right femoral position25 and right sided internal 
jugular veins in comparison with a left sided approach.28 To our knowledge, there is no data 
to clarify clinicians preference in relation to site, length or type. No previous  
 
or current RRT practice surveys have included vascular access as an item of interest. Our data 
from ANZ indicates that both right and left femoral veins are the sites of choice followed 
closely by right internal jugular (IJ) position. An access catheter length of 20 cm is the most 
common across all sites with just under half respondents indicating 24/25 cm length catheters 
used in femoral veins. This may reflect that a longer catheter is not considered necessary by 
some where the 20 cm version can be used in both femoral and IJ sites making ordering and 
stocking of the device simple. Others using the longer 24 or 25 cm catheter for femoral access 
in adults, may use this to place the catheter tip closer to the right atrium and would need to 
order and stock both lengths. 
Anticoagulation 
Responders to our survey indicate CRRT is often performed without the aid of an 
anticoagulant agent.  When patients received anticoagulation, unfractionated heparin (UFH) 
was the most common with over 80% of ICU’s using this strategy to extend circuit life. This is 
consistent with previous practice surveys from a decade earlier which also indicated UFH as 
the anticoagulation of choice.1,16 This approach is likely to be due to historical and predictable 
familiar use of this drug within medicine widely. Despite recent studies demonstrating better 
circuit life and literature guiding CRRT anticoagulation to regional techniques with citrate34-38 
this has not translated into current practice patterns with only a small proportion of 
responders indicating they frequently use the technique. A lack of historical and familiarity 
with this agent compared to heparin. Cost may also be a factor where heparin predominates. 
 
 
Strengths and limitations  
A strength of the study is the generalisability of the findings. Despite an unknown response 
rate, we gathered information from 106 hospitals in ANZ potentially representing 73% of all 
ICUs capable of performing RRT. This study therefore is the largest investigation of Australian 
and New Zealand CRRT practice ever conducted.   
Our study has several limitations. The accuracy of the responses could not be independently 
verified as the prescription of CRRT practice was self reported rather than by observation or 
collection of treatment data. Both pre RENAL10 and ATN surveys11 as well as recent practice 
surveys have used a self report approach. We did not obtain information about the use of, or 
prescribing practices associated with, alternative renal support therapies such as IHD or 
SLEDD. Despite some increasing interest in prolonged intermittent therapies such as SLEDD it 
has been previously reported that patients in ANZ ICUs spend < 5% of their renal support time 
receiving a therapy other than CRRT.11  We received 194 responses from 106 ICUs indicating 
multiple responders from a single ICU and the potential for reporting disagreement. Where 
multiple responses were received, individual surveys from the site were checked for 
consistency of practice patterns. For five sites with multiple responses and some 
inconsistencies in self reported practice, the individual sites were contacted for clarification 
of usual CRRT prescription in their critical care unit. 
Recommendations for research  
In this study we chose to determine current practices rather than explore clinicians 
perceptions of the optimal approaches to CRRT prescription or indeed if they prescribe based 
on any published evidence at all? It would be useful to explore individual clinician’s opinions 
regarding their practice of the therapy with specific themes of initiation or optimal  
 
timing of CRRT, dose prescription and modality choice for specific patient groups as well as 
how technical or practical prescription settings are decided in ICUs. In addition a cross 
sectional study or point prevalence study would provide more objective and reliable data for 
the prescription and delivery of RRT on ICU inpatients and further highlight consistent or 
indeed inconsistent current practices associated with renal support in the ANZ context and 
provide useful data that may help design control groups for future trials. In addition, there is 
a need to continue developing a data and evidence base for the most effective aspects of 
CRRT. There also appears to be a need to examine effective strategies for implementing 
results of past studies into daily practice. Data from large trials published has not changed 
many aspects of practice in ANZ. 
Summary  
We conducted a prospective survey of 194 clinicians from 106 ICUs in ANZ on the technical 
and practical aspects of CRRT prescription. Our findings suggest that a decade on from the last 
practice survey and the dissemination of ‘dose’ findings from ANZ there remains high 
variability in the practical prescription of CRRT. This lack of uniformity particularly in the areas 
of blood flow rates, access catheter length and replacement fluid site highlight the lack of 
adequate randomised controlled trials to provide evidence for guidelines associated with 
these settings. Variability in dose and dose prescription emphasize an inconsistent approach 
to therapy despite large RCTs and recommendations on the management of CRRT from 
recently published KDIGO guidelines. This study demonstrates the lack of standardisation in 
the application of CRRT in the critically ill. 
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Table 1. Profile of Survey respondents (n = 194) 
Demographic Variables Survey Respondents 
n (%) 
State Island or Territory  
Australian Capital Territory 3 (1.5%) 
New South Wales 51 (26.3%) 
Northern Territory 5 (2.6%) 
Queensland 36 (18.6%) 
South Australia 18 (9.3%) 
Tasmania 5 (2.6%) 
Victoria 53 (27.3%) 
Western Australia 14 (7.2%) 
North Island of New Zealand 8 (4.1%) 
South Island of New Zealand 1 (0.5%) 
  
Professional Role  
Consultant Intensivist 36 (18.6%) 
NUM (Charge Nurse) 11 (5.7%) 
ICU based Educator 37 (19.1%) 
Clinical Nurse Consultant 9 (4.6%) 
ANUM (Team leader) 12 (6.2%) 
Clinical Nurse Specialist 47 (24.2%) 
Registered Nurse 42 (21.6%) 
  
Hospital Type  
Regional Hospital 
Metropolitan  Private Hospital 
Metropolitan Public level 2 
Metropolitan Public Level 3 
53 (27.3%) 
19 (9.8%) 
30 (15.5%) 
92 (47.4%) 
  
ICU Type  
Adult Intensive Care 134 (69.1%) 
Paediatric Intensive Care 7 (3.6%) 
Combined Adult and Paediatric Intensive Care 53 (27.3%) 
  
ICU bed status  
0-5 beds 
6-10 beds 
11-15 beds 
16-20 beds 
 > 20 beds 
8 (4.1%) 
70 (36.1%) 
47 (24.2%) 
22 (11.3%) 
47 (24.2%) 
  
CRRT Yearly Treatments  
< 10 
11-25 
26-50 
51-75 
76-100 
>100 
Don’t know 
22 (11.3%) 
32 (16.5%) 
44 (22.7%) 
18 (9.3%) 
15 (7.7%) 
49 (25.3%) 
14 (7.2%) 
  
 
 
 
 Table 2. CRRT Prescription 
CVVHDF (no. + %)  Never Occasionally Frequently Always 
Dose Prescription  
(L/hr)  (n= 156) 
     
 1L (D) + 1L (R)  60 (38.4%) 35 (22.5%) 51 (32.7%) 10 (6.4%) 
 1.5L (D) + 1.5L (R)  52 (33.3%) 45 (28.9%) 56 (35.9%) 3 (1.9%) 
 2L (D) + 2L (R)  61 (39.1%) 55 (35.3%) 30 (19.2%) 10 (6.4%) 
 >2L (D) + >2L (R)  110 (70.5%) 34 (21.8%) 7 (4.5%) 5 (3.2%) 
Dose Prescription  
(mls/kg/hr) (n= 117) 
     
 0-15 mls/kg  90 (77%) 18 (15.4%) 6 (5.1%) 3 (2.5%) 
16-25 mls/kg  27 (23%) 23 (19.7%) 44 (37.6%) 23 (19.7%) 
 > 25 mls/kg  41 (35%) 30 (25.6%) 31 (26.6%) 15 (12.8%) 
Blood Flow rate      
(mls/min) ( n= 177)      
0-50 mls/min  168 (94.9%) 6 (3.4%) 3 (1.7%) 0 (0%) 
51-100 mls/min  152 (85.8%) 15 (8.5%) 10 (5.7%) 0 (0%) 
101-150 mls/min  85 (48%) 62 (35%) 25 (14.1%) 5 (2.9%) 
151-200 mls/min  24 (13.6%) 48 (27.1%) 80 (45.2%) 25 (14.1%) 
201-250 mls/min  57 (32.2%) 39 (22.1%) 68 (38.4%) 13 (7.3%) 
251-300 mls/min  92 (52%) 44 (24.9%) 35 (19.8%) 6 (3.3%) 
> 300 mls/min  155 (87.6%) 17 (9.6%) 2 (1.1%) 3 (1.7%) 
      
 
CVVH (no. + %)  Never Occasionally Frequently Always 
Dose Prescription  
(L/hr) ( n= 156) 
     
≤ 2 litres  116 (74.4%) 29 (18.5%) 4 (2.6%) 7 (4.5%) 
> 2 < 3 L  105 (67.3%) 20 (12.8%) 27 (17.3%) 4 (2.6%) 
> 3 L  120 (76.9%) 22 (14.1%) 12 (7.7%) 2 (1.3%) 
Dose Prescription  
(mls/kg/hr) ( n= 117) 
     
 0-15 mls/kg  108 (92.3%) 8 (6.8%) 1 (0.9%) 0 (0%) 
16-25 mls/kg  89 (76%) 17 (14.5%) 9 (7.7%) 2 (1.7%) 
 > 25 mls/kg  86 (73.5%) 12 (10.3%) 16 (13.7%) 3 (2.5%) 
Blood Flow rate      
(mls/min) ( n= 89)      
0-50 mls/min  82 (92%) 5 (5.6%) 2 (2.4%) 0 (0%) 
51-100 mls/min  76 (85.4%) 11 (12.3%) 2 (2.3%) 0 (0%) 
101-150 mls/min  53 (59.6%) 31 (34.8%) 5 (5.6%) 0 (0%) 
151-200 mls/min  17 (19.1%) 19 (21.3%) 38 (42.7%) 15 (16.9%) 
201-250 mls/min  25 (28%) 20 (22.5%) 35 (39.3%) 9 (10.2%) 
251-300 mls/min  40 (45%) 25 (28%) 21 (23.6%) 3 (3.4%) 
> 300 mls/min  74 (83%) 11 (12.4%) 2 (2.3%) 2 (2.3%) 
      
 
 
 
 
 
  
Table 3. Vascular access 
Vascular Access Responses  Never Occasionally Frequently Always 
Access Location 
 ( n= 194) 
      
Left Internal Jugular   15 (7.7%) 108 (55.7%) 69 (35.6%) 2 (1.0%) 
Right Internal Jugular   7 (3.6%) 65 (33.5%) 121 (62.4%) 1 (0.5%) 
Left Femoral    2 (1.0%) 57 (29.4%) 132 (68%) 3 (1.5%) 
Right Femoral   3 (1.5%) 51 (26.3%) 137 (70.6%) 3 (1.5%) 
Left Subclavian   69 (35.6%) 98 (50.5%) 26 (13.4%) 1 (0.5%) 
Right Subclavian   66 (34%) 103 (53.1%) 24 (12.4%) 1 (0.5%) 
Access Brand       
Bard Niagara  n= 133  66 (49.6%) 16 (12%) 34 (25.5%) 17 (12.8%) 
Gambro Dolphin n= 136  85 (62.5%) 9 (6.6%) 18 (13.2%) 24 (17.7%) 
Quinton Mahurkar  n= 119  114 (95.8%) 4 (3.4%) 1 (0.8%) 0 (0%) 
Medcomp  n= 119  110 (92.4%) 0 (0%) 8 (6.7%) 1 (0.8%) 
Arrow  n= 137  49 (35.8%) 30 (21.9%) 32 (23.4%) 26 (19%) 
Cook  n= 128  84 (65.6%) 17 (13.3%) 19 (14.8%) 8 (6.3%) 
Don’t Know )(n= 63)       
Vascular Access length (cm) 
 
  15 cm 20 cm 24/25 cm  
Internal Jugular  n= 150  94 (62.7%) 55 (36.7%) 1 (0.6%)  
Femoral n= 150  4 (2.6%) 76 (50.7%) 70 (46.7%)  
Subclavian n= 150  85 (56.7%) 60 (40%) 5 (3.3%)  
Don’t Know (n= 44)       
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
Figure 1. Anticoagulation for CRRT 
 
 
 
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
Anticoagulation for CRRT
Never Occasionally Frequently Always
